US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

VanEck Uranium and Nuclear ETF

97.61

-0.9400-0.95%

Post-market: 97.610.00000.00%19:43 EDT

Volume:202.72K

Turnover:19.88M

Market Cap:1.28B

PE:- -

High:99.33

Open:99.18

Low:96.94

Close:98.55

Loading ...

Overview Company News Filings

10 Nuclear Stocks Expected to Rise as Much as 94% After Meta-Constellation Deal

Nuclear Stocks Get Boost After Report Says Trump Will Sign Orders to Jumpstart Field. NNE, Centrus up 16%; Oklo up 14%

BriaCell Reports “Late-Breaker” Phase 3 Data at AACR 2025: Positive Tolerability Profile and Potential Response Biomarkers Identified

Indaptus Therapeutics Chief Medical Officer Roger Waltzman, M.D., M.B.A. to Moderate Panel at CMO360 Summit

Indaptus Therapeutics Initiates Phase 1 Combination Study of Decoy20 with PD-1 Checkpoint Inhibitor Tislelizumab

Press Release: Indaptus Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Corporate Update

Indaptus Therapeutics Expands Patent Portfolio in China, Japan, and Israel, Strengthening its Intellectual Property for Infectious Disease and Cancer Treatments

Indaptus Therapeutics’ Chief Scientific Officer Dr. Michael Newman to Present at the 10th Annual Innate Killer Summit

Pacific Gas & Electric Holds The Line On Q4 EPS Amid Grid Modernization Push: Details

Indaptus Therapeutics Receives Approval from Health Canada to Expand Clinical Trial of Decoy20

Indaptus Therapeutics Provides Year-End Review and Outlook for 2025

BriaCell 2024 SABCS® Poster Highlights Ability of Bria-IMT™ Regimen to Increase Cancer-Fighting Immune Cells in Metastatic Breast Cancer

BriaCell Presents Unprecedented Overall Survival Data in Metastatic Breast Cancer in Spotlight Poster at 2024 SABCS®

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/NLR/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NLR","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NLR\",,,,,undefined,":{"symbol":"NLR","market":"US","secType":"STK","nameCN":"VanEck Uranium and Nuclear ETF","latestPrice":97.61,"timestamp":1749153600000,"preClose":98.55,"halted":0,"volume":202716,"hourTrading":{"tag":"盘后","latestPrice":97.61,"preClose":97.61,"latestTime":"19:43 EDT","volume":314,"amount":30659.21,"timestamp":1749167016081},"delay":0,"floatShares":13141632,"shares":13141632,"eps":0,"marketStatus":"Not Yet Opened","change":-0.94,"latestTime":"06-05 16:00:00 EDT","open":99.18,"high":99.33,"low":96.94,"amount":19875071.28672,"amplitude":0.024252,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1749196800000},"marketStatusCode":0,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":98.55,"sharesOutstanding":13141632,"nav":98.0815,"aum":1288951041.69,"dividendRate":0.006249,"bidAskSpread":0.002487,"preHourTrading":{"tag":"盘前","latestPrice":98.94,"preClose":98.5499,"latestTime":"09:27 EDT","volume":688,"amount":67991.59312,"timestamp":1749130061513},"postHourTrading":{"tag":"盘后","latestPrice":97.61,"preClose":97.61,"latestTime":"19:43 EDT","volume":314,"amount":30659.21,"timestamp":1749167016081},"volumeRatio":0.477153,"impliedVol":0.2376,"impliedVolPercentile":0.468},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NLR\",,,,,undefined,":{"symbol":"NLR","floatShares":13141632,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.477153,"shares":13141632,"dividePrice":0.61,"high":99.33,"amplitude":0.024252,"preClose":98.55,"low":96.94,"week52Low":64.26,"pbRate":"--","week52High":101.69,"institutionHeld":0,"latestPrice":97.61,"eps":0,"divideRate":0.006249,"volume":202716,"delay":0,"ttmEps":0,"open":99.18,"prevYearClose":81.34,"prevWeekClose":97.19,"prevMonthClose":97.19,"prevQuarterClose":73.27,"fiveDayClose":97.26,"twentyDayClose":83.75,"sixtyDayClose":75.39},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NLR\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2540800705","title":"10 Nuclear Stocks Expected to Rise as Much as 94% After Meta-Constellation Deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2540800705","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540800705?lang=en_us&edition=fundamental","pubTime":"2025-06-04 10:15","pubTimestamp":1749003300,"startTime":"0","endTime":"0","summary":"Big Tech companies are scrambling to secure electricity for the long term. For many, this means investing in nuclear power generation.Constellation Energy Corp.’s Clinton Clean Energy Center in Rural ","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"cff4bfcccca11b1966c7f7a68be45152","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1551013425.SGD","NLR","PCG","FELTY","PDN.AU","LU0786609619.USD","LU0215105999.USD","LU0256863902.USD","LU1145028129.USD","LU1119994496.HKD","NUKZ","CEG","LU0203202063.USD","DNN","SG9999015978.USD","LU1316542783.SGD","URAN","LU1868836914.USD","LU1074936037.SGD","LU2458330243.SGD","LU0072462426.USD","LU0225283273.USD","LU0053666078.USD","LU1366333091.USD","IE00BJTD4N35.SGD","LU0433182093.SGD","LU0878866978.SGD","LU1564329115.USD","IE00B4JS1V06.HKD","LU0980610538.SGD","IE00BD4GTT62.SGD","LU1674673428.USD","LU0444973449.USD","BK4081","LU2065171311.SGD","LU2458330169.SGD","LU2237957902.USD","LU0208291251.USD","IE0009356076.USD","LU0708995401.HKD","NXE","FLS","LU2420271590.USD","01816","LU0096364046.USD","LU1823568750.SGD","HTHIY","IE00BJTD4V19.USD","LU1084165304.USD","LU0690374615.EUR","LU1366192091.USD","LU0149725797.USD","LU2023250504.SGD","LU2461242641.AUD","IE00B775H168.HKD","URA"],"gpt_icon":1},{"id":"2537997877","title":"Nuclear Stocks Get Boost After Report Says Trump Will Sign Orders to Jumpstart Field. NNE, Centrus up 16%; Oklo up 14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2537997877","media":"Dow Jones","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537997877?lang=en_us&edition=fundamental","pubTime":"2025-05-23 06:48","pubTimestamp":1747954080,"startTime":"0","endTime":"0","summary":"Nuclear-industry stocks were trading higher after Reuters reported that President Trump is expected to sign executive orders by as soon as Friday that aim to jumpstart the nuclear-energy industry.The report, which cited sources familiar with the matter, said the orders would attempt to ease the regulatory process on approvals for new reactors, as well as strengthen fuel supply chains.In after-hours trading, shares of Lightbridge rose 11% to $11.87, shares of NuScale Power climbed 11% to $28.08 and shares of Centrus Energy jumped 12%, to $103.94.VanEck Uranium & Nuclear, an exchange-traded fund comprising uranium and nuclear stocks, ticked 2% higher, to $89.99, in post-market trading.A draft summary of the orders noted that Trump will invoke the Cold War-era Defense Production Act, allowing him to declare a national emergency over U.S. dependence on Russia and China for enriched uranium, nuclear fuel processing and advanced reactor inputs, the Reuters report said.","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"6c28022d5a031ed9d134f6e9ef2b6376","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Nuclear Stocks Get Boost After Report Says Trump Will Sign Orders to Jumpstart Field","news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LEU","NLR","UUUU","BK4182","OKLO","SMR","LTBR","BK4606","NNE","BK4563","BK4156"],"gpt_icon":0},{"id":"2531303571","title":"BriaCell Reports “Late-Breaker” Phase 3 Data at AACR 2025: Positive Tolerability Profile and Potential Response Biomarkers Identified","url":"https://stock-news.laohu8.com/highlight/detail?id=2531303571","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531303571?lang=en_us&edition=fundamental","pubTime":"2025-04-30 19:30","pubTimestamp":1746012600,"startTime":"0","endTime":"0","summary":"Phase 3 clinical data shows potential predictive biomarkers for treatment response, first identified in Phase 2 study. Biomarkers could be utilized to predict and provide better patient outcomes, including response rates and survival benefits. Positive delayed-type hypersensitivity   and a favorable Neutrophil-to-Lymphocyte Ratio   linked to longer progression-free survival  in Phase 3 patients. Presence of Circulating Tumor Cells  after patients’ initial Phase 3 treatment supports role as negative prognostic marker . Bria-IMT Phase 3 regimen was well-tolerated with a preferred tolerability profile. “Using biomarkers as powerful instruments to predict patient responsiveness to the Bria-IMT treatment would allow physicians and oncologists to identify potential responders sooner, providing better clinical outcomes and ultimately extending patients’ lives,” stated Carmen Calfa, MD, Clinical Research Lead for the breast site disease group at the University of Miami Miller School of Medicin","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/briacell-reports-breaker-phase-3-113000083.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BCTXZ","BK4211","BCTX","BK4097","BK4139","DTH","PFS","BK4606","OS","NLR","BK4129","CAML","TPC","BK4195","BCTXW"],"gpt_icon":0},{"id":"2522222180","title":"Indaptus Therapeutics Chief Medical Officer Roger Waltzman, M.D., M.B.A. to Moderate Panel at CMO360 Summit","url":"https://stock-news.laohu8.com/highlight/detail?id=2522222180","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522222180?lang=en_us&edition=fundamental","pubTime":"2025-03-25 20:00","pubTimestamp":1742904000,"startTime":"0","endTime":"0","summary":"NEW YORK, March  25, 2025  (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical-stage biotechnology company pioneering innovative therapies for cancer and viral infections, annou","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/25/3048658/0/en/Indaptus-Therapeutics-Chief-Medical-Officer-Roger-Waltzman-M-D-M-B-A-to-Moderate-Panel-at-CMO360-Summit.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","BK4606","SMMF","BK4211","BK4139","NLR"],"gpt_icon":0},{"id":"2520678244","title":"Indaptus Therapeutics Initiates Phase 1 Combination Study of Decoy20 with PD-1 Checkpoint Inhibitor Tislelizumab","url":"https://stock-news.laohu8.com/highlight/detail?id=2520678244","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520678244?lang=en_us&edition=fundamental","pubTime":"2025-03-18 20:00","pubTimestamp":1742299200,"startTime":"0","endTime":"0","summary":"New trial arm to evaluate safety, dosing and preliminary anti-tumor activity in advanced solid tumors. NEW YORK, March 18, 2025  -- Indaptus Therapeutics, Inc. , a clinical-stage biotechnology company dedicated to developing novel treatments for cancer and viral infections, today announced that it has advanced toa new expansion arm of its Phase 1b/2 clinical trial of Decoy20. This expansion will evaluate the combination of Decoy20 with BeiGene’s PD-1 checkpoint inhibitor, tislelizumab, with a focus on safety, dose optimization, and early signs of anti-tumor activity.Jeffrey Meckler, CEO of Indaptus, commented, “This marks a pivotal step forward for Indaptus and our Decoy platform. Preclinical research has consistently shown that Decoy20 works synergistically with a checkpoint inhibitor, and we now have the opportunity to test that in patients for the first time. While this initial phase will focus on safety and tolerability, we are laying the groundwork for what could be a game-changin","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/indaptus-therapeutics-initiates-phase-1-120000013.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LENZ","PD","BK4139","NLR","LU1169589451.USD","BK4606","INDP","LU1169590202.USD","BK4023"],"gpt_icon":1},{"id":"2519386248","title":"Press Release: Indaptus Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2519386248","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519386248?lang=en_us&edition=fundamental","pubTime":"2025-03-13 19:30","pubTimestamp":1741865400,"startTime":"0","endTime":"0","summary":"Indaptus Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Corporate Update. -- Company Achieves Key Clinical Milestone with more than 20 Patients. Enrolled in Weekly Dosing Cohort of Phase 1 Trial of Decoy20. -- Pharmacodynamic immune activation biomarker and pharmacokinetics profiles. in initial data sets appear to meet or exceed initial expectations. -- Early signs of potential benefit emerge with some patients demonstrating. Jeffrey Meckler, Chief Executive Officer of Indaptus, commented, \"We continue to make significant progress in our Phase 1 trial of Decoy20, and enrolling more than 20 patients in the weekly dosing cohort marks an important milestone. We are particularly encouraged by the emerging clinical data, with some patients in this cohort demonstrating stable disease - an early sign that Decoy20's immune-modulating approach may be having a meaningful impact. With a favorable safety profile observed so far, we are focused on efficiently a","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INDP","BK4231","BK4080","LENZ","BK4606","NLR","SITC","BK4139"],"gpt_icon":0},{"id":"2516675441","title":"Indaptus Therapeutics Expands Patent Portfolio in China, Japan, and Israel, Strengthening its Intellectual Property for Infectious Disease and Cancer Treatments","url":"https://stock-news.laohu8.com/highlight/detail?id=2516675441","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516675441?lang=en_us&edition=fundamental","pubTime":"2025-03-04 21:00","pubTimestamp":1741093200,"startTime":"0","endTime":"0","summary":"NEW YORK, March 04, 2025  -- Indaptus Therapeutics, Inc. , a clinical-stage biotechnology company dedicated to developing novel treatments for cancer and viral infections, announced today that it has secured new patent approvals in China, Japan and Israel for its Decoy platform. These patents cover the use of Decoy bacteria compositions for preventing or treating Hepatitis B virus  and human immunodeficiency virus  – two diseases that continue to pose major global health challenges. The patents also extend to combination therapies with a variety of both approved and investigational treatments.Dr. Michael Newman, Founder and Chief Scientific Officer of Indaptus, commented, “The allowance of these patents in key international markets highlights the potential of our Decoy platform in the fight against chronic infectious diseases. With millions of people affected by HBV and HIV worldwide, expanding our intellectual property reinforces the novelty and therapeutic promise of our approach.”","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/indaptus-therapeutics-expands-patent-portfolio-130000815.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["NLR","BK4606","LENZ","BK4139","INDP"],"gpt_icon":0},{"id":"2514579099","title":"Indaptus Therapeutics’ Chief Scientific Officer Dr. Michael Newman to Present at the 10th Annual Innate Killer Summit","url":"https://stock-news.laohu8.com/highlight/detail?id=2514579099","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514579099?lang=en_us&edition=fundamental","pubTime":"2025-02-25 21:00","pubTimestamp":1740488400,"startTime":"0","endTime":"0","summary":"NEW YORK, Feb.  25, 2025  (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical-stage biotechnology company dedicated to developing novel treatments for cancer and viral infection","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/02/25/3031951/0/en/Indaptus-Therapeutics-Chief-Scientific-Officer-Dr-Michael-Newman-to-Present-at-the-10th-Annual-Innate-Killer-Summit.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NLR","BK4211","SMMF","LENZ","BK4606","BK4139"],"gpt_icon":0},{"id":"2511078618","title":"Pacific Gas & Electric Holds The Line On Q4 EPS Amid Grid Modernization Push: Details","url":"https://stock-news.laohu8.com/highlight/detail?id=2511078618","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511078618?lang=en_us&edition=fundamental","pubTime":"2025-02-15 01:30","pubTimestamp":1739554227,"startTime":"0","endTime":"0","summary":"PG&amp;E reports Q4 results in line with consensus, 2024 adjusted EPS up aided by higher investment, plans to support 5.5 GW of new data center demand.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/25/02/43738960/whats-going-on-with-pacific-gas-electric-shares-on-friday","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RNWZ","PCG","NLR"],"gpt_icon":0},{"id":"2509573283","title":"Indaptus Therapeutics Receives Approval from Health Canada to Expand Clinical Trial of Decoy20","url":"https://stock-news.laohu8.com/highlight/detail?id=2509573283","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509573283?lang=en_us&edition=fundamental","pubTime":"2025-02-05 21:00","pubTimestamp":1738760400,"startTime":"0","endTime":"0","summary":"NEW YORK, Feb. 05, 2025  -- Indaptus Therapeutics, Inc.  , a clinical-stage biotechnology company pioneering innovative cancer and viral infection treatments, today announced the Company has received Clinical Trial Authorization from Health Canada to initiate its clinical trial for its lead asset, Decoy20. This approval will allow the Company to expand its ongoing U.S. clinical trial, INDP-D101, to Canadian sites, broadening patient recruitment and enhancing its clinical research program. The trial will enroll patients in Canada under the current protocol, which involves weekly dosing of Decoy20. Indaptus also plans to submit an amendment to Health Canada to incorporate its upcoming combination trial, which pairs Decoy20 with Beigene’s PD-1 checkpoint inhibitor,tislelizumab.Jeffrey Meckler, CEO of Indaptus, commented, “We are pleased to bring Canadian investigators and patients into our clinical efforts, creating a more diverse and robust data set. Health Canada’s approval followed a c","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/indaptus-therapeutics-receives-approval-health-130000809.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","LENZ","INDP","BK4606","NLR"],"gpt_icon":0},{"id":"2501721041","title":"Indaptus Therapeutics Provides Year-End Review and Outlook for 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2501721041","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501721041?lang=en_us&edition=fundamental","pubTime":"2025-01-08 21:00","pubTimestamp":1736341200,"startTime":"0","endTime":"0","summary":"Continued Strong Clinical Progress and Planned New Combination Trial Provide Significant Momentum for 2025. NEW YORK, Jan. 08, 2025  -- Indaptus Therapeutics, Inc.  , a clinical-stage biotechnology company pioneering innovative cancer and viral infection treatments, today highlights its accomplishments in 2024 and outlines the Company’s strategic goals for the year ahead.Advancing Decoy20 in Clinical Trials2024 was a year of meaningful progress for Indaptus’ lead clinical candidate, Decoy20, a novel immunotherapy designed to harness both innate and adaptive immune responses. Highlights from the Company’s Phase 1 clinical trial include:. Second Cohort Results : Building on the Company’s November 2023 findings, Decoy20 demonstrated a broad immune response across multiple tumor types in patients, underscoring the platform’s potential as a monotherapy.Weekly-Dose Cohort Initiation : After receiving Safety Review Committee approval, the Company dosed its first patient in the weekly-dose por","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/indaptus-therapeutics-provides-end-review-130000198.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4231","BK4139","NLR","BK4080","SITC","LENZ","INDP"],"gpt_icon":0},{"id":"2491322908","title":"BriaCell 2024 SABCS® Poster Highlights Ability of Bria-IMT™ Regimen to Increase Cancer-Fighting Immune Cells in Metastatic Breast Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2491322908","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491322908?lang=en_us&edition=fundamental","pubTime":"2024-12-13 20:50","pubTimestamp":1734094200,"startTime":"0","endTime":"0","summary":"BriaCell reports influx of cancer fighting CD8+ “killer” T cell into metastatic breast cancer tumors and lymph organs turning “Cold” tumors and lymph nodes “Hot” on ImmunoPET imaging in cancer patient","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/12/13/2996746/0/en/BriaCell-2024-SABCS-Poster-Highlights-Ability-of-Bria-IMT-Regimen-to-Increase-Cancer-Fighting-Immune-Cells-in-Metastatic-Breast-Cancer.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NLR","CPI","ABIL","BCTX"],"gpt_icon":0},{"id":"2490212859","title":"BriaCell Presents Unprecedented Overall Survival Data in Metastatic Breast Cancer in Spotlight Poster at 2024 SABCS®","url":"https://stock-news.laohu8.com/highlight/detail?id=2490212859","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490212859?lang=en_us&edition=fundamental","pubTime":"2024-12-11 20:50","pubTimestamp":1733921400,"startTime":"0","endTime":"0","summary":"Median overall survival (OS) to date of 13.4 months for Phase 2 patients treated with the Phase 3 formulation (15.6 months for those treated since 2022), double that of comparable patients in the lite","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/12/11/2995320/0/en/BriaCell-Presents-Unprecedented-Overall-Survival-Data-in-Metastatic-Breast-Cancer-in-Spotlight-Poster-at-2024-SABCS.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MBC","NLR","BK4135","CPI","DTH","BK4097","OS","BK4086","CNS"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":13,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NLR\",params:#limit:5,,,undefined,":[{"date":"2024-12-23","symbol":"NLR","amount":0.6142,"announcedDate":"2024-12-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-23","defaultRemindTime":1734964200000,"name":"核能指数ETF-Market Vectors","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-24","payableDate":"2024-12-23","currency":"USD","dateTimestamp":1734930000000,"payDate":"2024-12-24"},{"date":"2023-12-18","symbol":"NLR","amount":3.258,"announcedDate":"2023-12-15","type":"dividend","market":"US","newRecordDate":"2023-12-19","defaultRemindTime":1702909800000,"name":"核能指数ETF-Market Vectors","recordDate":"2023-12-22","payableDate":"2023-12-19","currency":"USD","dateTimestamp":1702875600000,"payDate":"2023-12-22"},{"market":"US","date":"2022-12-19","symbol":"NLR","amount":1.1093,"defaultRemindTime":1671460200000,"name":"核能指数ETF-Market Vectors","recordDate":"2022-12-23","payableDate":"2022-12-20","currency":"USD","type":"dividend","dateTimestamp":1671426000000},{"market":"US","date":"2021-12-20","symbol":"NLR","amount":1.091,"defaultRemindTime":1640010600000,"name":"核能指数ETF-Market Vectors","recordDate":"2021-12-27","payableDate":"2021-12-21","currency":"USD","type":"dividend","dateTimestamp":1639976400000},{"market":"US","date":"2020-12-21","symbol":"NLR","amount":1.0964,"name":"核能指数ETF-Market Vectors","recordDate":"2020-12-28","payableDate":"2020-12-22","currency":"USD","type":"dividend","dateTimestamp":1608526800000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NLR\",market:\"US\",,,undefined,":[{"executeDate":"2015-12-21","recordDate":"2015-12-23","paymentDate":"2015-12-28","value":1.486,"currency":"USD"},{"executeDate":"2016-12-19","recordDate":"2016-12-21","paymentDate":"2016-12-23","value":1.719,"currency":"USD"},{"executeDate":"2018-12-20","recordDate":"2018-12-21","paymentDate":"2018-12-27","value":1.936,"currency":"USD"},{"executeDate":"2019-12-23","recordDate":"2019-12-24","paymentDate":"2019-12-30","value":1.072,"currency":"USD"},{"executeDate":"2020-12-21","recordDate":"2020-12-22","paymentDate":"2020-12-28","value":1.0964,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NLR\",market:\"US\",delay:false,,,undefined,":{}}}